BIO '99 To Feature Presentations on Genomics, Molecular Medicine
WASHINGTON, D.C. (April 15, 1999) Genomics is revolutionizing biology and biotechnology research, greatly accelerating the discovery of new therapies and cures for some of the most intractable and life-threatening diseases.
The BIO '99 International Biotechnology Meeting & Exhibition in Seattle, Washington, May 16 May 20, will feature world renown researchers and biotechnology and pharmaceutical company executives discussing the impact of genomics.
On Monday, May 17, a symposium titled, "The Genomics of Cancer," will look at how analysis of gene expression in cancer cells is revealing new drug targets. Featured speakers are Drs. Mary Claire King and Eric Lynch, of the University of Washington; Dr. Douglas Ross, of Stanford University; and Dr. Gregory Riggins, of Duke University.
On Tuesday, May 18, a symposium titled, "The Genomic Revolution: Creating New Opportunities For Biotechnology in the 21st Century," will examine the ways genetic revelations are changing medical research. Featured speakers are Drs. Leroy Hood and Rudi Aebersold, of the University of Washington; Dr. Richard Klausner, director of the U.S. National Cancer Institute; Dr. Gerald Rubin, of University of California at Berkeley; Dr. David Galas, of the Keck Graduate Institute of Applied Life Sciences; and Dr. C. Thomas Caskey, senior vice president of Merck & Co. Inc.
On Wednesday, May 19, a symposium titled, "The Future of Molecular Medicine," will explore the impact of genomics on the next generation of drugs, including prognostications about new therapies that will be available to consumers in the next 5 to 15 years. Featured speakers are Immunex Chairman and CEO Edward Fritzky; Corixa Corp. President and CEO Steven Gillis; Bayer Corp. Senior Vice President Wolf-Dieter Busse; Sphinx Pharmaceuticals President Martin Haslanger; and the Wall Street Journal's Michael Waldholtz.
The annual meeting of the Biotechnology Industry Organization (BIO) is the world's largest exhibition of its kind. A record 5,000 company executives, scientists, investment experts and government officials from 40 nations are expected to attend. The conference will feature more than 125 presentations including developments in medical, agricultural and industrial biotechnology. More than 500 exhibitors also will display their most up-to-date product innovations.
A full program of BIO '99 symposia, presentations and events is available on BIO's website at www.bio.org. BIO '99 will take place at the Washington State Convention & Trade Center in Seattle.
Registration for credentialed press is complimentary. A fully operational press room with computers and Internet access will be available. To register contact BIO's Charles Craig at (202) 962-9200.
###